New Taipei Municipal TuCheng Hospital
New Taipei City, Taiwan
NCT Number: NCT07078955
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 2
New Taipei City, Taiwan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A topical drop of 0.03% BRM421 ophthalmic solution.
A topical drop of Artificial Tear.
A topical drop of 0.06% BRM421 ophthalmic solution.
Time frame: 6 weeks
Total corneal fluorescein staining (tCFS) score by using NEI Scale (0-20, higher scores mean a worse outcome)
Contact information is provided by the study sponsor or research team.
BRIM Biotechnology Inc.
Industry
A Phase 2, Multicenter, Randomized, Open-Labeled, Artificial Tear-Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07050446
Asthenopia, Conjunctival Diseases
Belgrade, Serbia
View Trial DetailsNCT07715266
Cataract Surgery, Dry Eye Disease (DED)
Alicante, Spain
View Trial DetailsNCT07671222
Arthritis, Arthritis, Rheumatoid
Mexico City, Mexico
View Trial DetailsNCT07633938
Dry Eye Disease (DED), Dry Eye Syndromes
Guangzhou, Guangdong, China
View Trial Details